Praveen Gundelly, MD
Infectious Disease · Cleveland, OHNPI 1700033313
Payments from drug & device makers
Across 125 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$597
- Merck$383
- Melinta Therapeutics, LLC$260
- Johnson & Johnson$213
- Insmed, Inc.$195
- Shionogi Inc$155
- plus $586 from 9 others
What the payments were for
- Food & beverage$2,378100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 33 | $597 |
| Merck | 23 | $383 |
| Melinta Therapeutics, LLC | 12 | $260 |
| Johnson & Johnson | 9 | $213 |
| Insmed, Inc. | 11 | $195 |
| Shionogi Inc | 6 | $155 |
| Viiv Healthcare Company | 9 | $146 |
| AbbVie | 5 | $115 |
| Astellas Pharma US Inc | 5 | $112 |
| Tetraphase Pharmaceuticals, Inc. | 4 | $62 |
| Aimmune Therapeutics, Inc. | 2 | $46 |
| La Jolla Pharmaceutical Company | 2 | $37 |
| Theratechnologies Inc. | 2 | $36 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| Napo Pharmaceuticals Inc | 1 | $15 |
How this compares
$2,389 in reported general payments places this provider in the 70th percentile of 308 infectious disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 18 | $18,629 |
| Valganciclovir Hcl | 13 | $6,485 |
| Cefepime Hcl | 25 | $3,857 |
| Cefazolin Sodium | 12 | $1,082 |
| Cephalexin | 43 | $969 |
| Vancomycin Hcl | 14 | $864 |
| Cefadroxil | 23 | $801 |
| NitrofurantoinNitrofurantoin Macrocrystal | 22 | $578 |
| Sodium Chloride0.9 % Sodium Chloride | 35 | $531 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 28 | $499 |
| Doxycycline Hyclate | 22 | $471 |
| Acyclovir | 11 | $264 |
| Amoxicillin | 15 | $182 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 21 | $115 |
| Ciprofloxacin Hcl | 18 | $97 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Cleveland
- Robert SalataCleveland$2.8M
- Curtis DonskeyCleveland$1.6M
- Robin JumpCleveland$1.2M
- Grace McComseyCleveland$1M
- Robert BonomoCleveland$1M
- Elie SaadeCleveland$470K
- Corrilynn HilemanCleveland$361K
- Ann AveryCleveland$298K
- Jill MiracleCleveland$175K
- Melissa JenkinsCleveland$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.